Working… Menu

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02655458
Recruitment Status : Completed
First Posted : January 14, 2016
Last Update Posted : August 18, 2017
Bristol-Myers Squibb
Information provided by (Responsible Party):
Hearn Jay Cho, Icahn School of Medicine at Mount Sinai

Brief Summary:

The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance to see what side effects it may have and how well it works for the treatment of symptomatic multiple myeloma diagnosed and treated with induction therapy in the past year.

Induction therapy is the first phase of treatment for multiple myeloma. The goal of induction therapy for multiple myeloma is to reduce the number of plasma cells in the bone marrow and the proteins that the plasma cells produce. Induction therapy is usually given for 3-4 weeks.

An autologous peripheral blood stem cell transplant is a procedure in which immature "stem cells" are collected and stored for future use. A high dose of chemotherapy is given to the patient to destroy myeloma cells, and the patient's stem cells are replaced.

The investigational drug in this program is elotuzumab. Elotuzumab is known as BMS-901608. Elotuzumab is a manufactured protein directed against a target found on multiple myeloma cells. Lenalidomide is currently approved for patients with multiple myeloma. Melphalan and cyclophosphamide, the drugs used during stem cell collection and transplant, are also approved by the U.S. FDA. Melphalan is an FDA-approved chemotherapy for multiple myeloma and is used as high-dose treatment prior to stem cell transplantation. Cyclophosphamide is an FDA-approved chemotherapy that may be used, either alone, or in combination with other drugs to treat multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Elotuzumab Drug: Lenalidomide Other: autologous PBMC reconstitution Other: ASCT Phase 1

Detailed Description:

This is a Phase 1b, open-label, trial investigating elotuzumab and autologous PBMC reconstitution with auto-SCT consolidation therapy and lenalidomide maintenance. Fifteen patients will be enrolled in this study.

This study is based on the hypothesis that the addition of Elotuzumab and autologous PBMC reconstitution to standard-of-care auto-SCT and lenalidomide maintenance will be safe and feasible. Furthermore, we hypothesize that Elotuzumab and PBMC reconstitution will target residual myeloma cells, enhance NK cell activation and ADCC, and promote tumor-specific humoral and cellular immune responses against myeloma cells, resulting in long-term maintenance of the minimal residual disease state.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
Study Start Date : January 2016
Actual Primary Completion Date : July 13, 2017
Actual Study Completion Date : July 13, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: autologous PBMC reconstitution, Elotuzumab, Lenalidomide
Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
Drug: Elotuzumab

The following must also be administered before any elotuzumab:

Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po).

Other Name: Empliciti

Drug: Lenalidomide
On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
Other Name: Revlimid

Other: autologous PBMC reconstitution
Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.

Other: ASCT
Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are "harvested," stored and then returned to the body (engrafted). To be done as part of standard of care.
Other Name: auto-SCT consolidation therapy

Primary Outcome Measures :
  1. Incidence of completion of treatment [ Time Frame: up to 24 months ]
    Safety and tolerability will be measured by the number of evaluable patients who complete the treatment protocol.

Secondary Outcome Measures :
  1. IFE level [ Time Frame: up to 24 months ]
    Immunofixation Serum Test (IFE) level

  2. sFLC level [ Time Frame: up to 24 months ]
    Serum Free Light Chain analysis (sFLC) level

  3. Bone marrow MRD analysis [ Time Frame: up to 24 months ]
    Bone marrow disease (MRD) is the name for small numbers of leukaemic cells in the bone marrow

  4. Progression-Free Survival [ Time Frame: up to 24 months ]
    number of participants at 24 months who are progression-free

  5. CyTOF mass cytometry [ Time Frame: up to 24 months ]
    Immune cell reconstitution will be assessed by Cytometry by Time-Of-Flight (CyTOF) mass cytometry. This method quantifies and characterizes all cellular immune compartments.

  6. SPEP level [ Time Frame: up to 24 hours ]
    Serum protein electrophoresis (SPEP) level

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  • Subject has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care.

Target Population

  • Subjects with symptomatic MM by IMWG criteria who are receiving or have completed induction chemotherapy, who have achieved at least a PR on most recent therapy by IMWG criteria, and are eligible for auto-SCT for consolidation. A specific induction regimen is not dictated for this protocol, however, the induction regimen must not have contained melphalan (L-PAM, Alkeran).
  • Age > 18 years or legal age of consent per local regulations.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.
  • Documented evidence of newly diagnosed, symptomatic MM, by IMWG criteria within one year of enrollment
  • Prior lenalidomide exposure is permitted only if the subject did not discontinue lenalidomide due to a related, grade ≥ 3 AE. Age and Reproductive Status
  • Men and women of childbearing potential (WOCBP) must be using 2 reliable methods of contraception to avoid pregnancy throughout the study for a period of at least 30 days before and 90 days after the last dose of investigational product in such a manner that the risk of pregnancy is minimized. See Section 4.3.3 for the definition of WOCBP and also refer to the Revlimid Risk Management Plan guidelines.
  • WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG). The first should be performed within 10 to 14 days and the second within 24 hours prior to the start of the study drug. A prescription for lenalidomide for a female of childbearing potential must not be issued by the prescriber until negative pregnancy tests have been verified by the prescriber.
  • Women must not be breastfeeding.
  • Men must agree to use a latex condom and a second form of birth control during sexual contact with WOCBP, even if they have had a successful vasectomy, and must agree not to donate sperm during study drug therapy and for 90 days after therapy.
  • Subjects must be willing to refrain from blood donations during study drug therapy and for 8 weeks after therapy.

Exclusion Criteria:

Target Disease

  • MGUS, Waldenström's macroglobulinemia, or asymptomatic (smoldering) myeloma.
  • Active plasma cell leukemia (defined as either 20% of peripheral white blood cells comprised of plasma/CD138+ cells or an absolute plasma cell count of 2 x 109/L).

Medical History and Concurrent Diseases

  • All AEs of any prior chemotherapy, surgery, or radiotherapy not resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v.4.0) Grade ≤ 2.
  • POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
  • Acute renal failure due solely to readily reversible causes such as hypercalcemia, hyperuricemia, dehydration, hyperviscosity, or acute tubular necrosis from nephrotoxic drugs.
  • Significant cardiac disease as determined by the investigator including:

    1. Known or suspected cardiac amyloidosis
    2. Congestive heart failure of Class III or IV of the NYHA classification
    3. Uncontrolled angina, hypertension or arrhythmia
    4. Myocardial infarction in the past 6 months
    5. Any uncontrolled or severe cardiovascular disease
  • Prior cerebrovascular event with persistent neurologic deficit.
  • Known HIV Infection or active hepatitis A, B or C.
  • Any medical conditions that, in the investigator's opinion, would impose excessive risk to the subject.

Examples of such conditions include:

a. Any uncontrolled disease, such as pulmonary disease, infection, seizure disorder b. Any altered mental status or any psychiatric condition that would interfere with the understanding of the informed consent c. Active infection that requires parenteral anti-microbial or anti-parasitic treatment

  • Prior or concurrent malignancy, except for the following:

    1. Adequately treated basal cell or squamous cell skin cancer;
    2. Or any other cancer from which the subject has been disease-free for > 5 years
  • Uncontrolled diabetes (defined as Hgb A1C > 8.0%)
  • Unable to tolerate thromboembolic prophylaxis including, as clinically indicated, aspirin, Coumadin (warfarin) or dose adjusted low-molecular weight heparin. Physical and Laboratory Test Findings
  • Corrected serum calcium > 11.5 mg/dl within 2 weeks of enrollment.
  • Absolute neutrophil count < 1000 cells/mm3. No granulocyte colony stimulating factors (G-CSF or GMCSF) allowed within 1 week of enrollment. No pegylated granulocyte colony stimulating factors are allowed within 3 weeks of treatment start.
  • Platelets < 75,000 cell/mm3 (75 x 109/L). Qualifying laboratory value must occur at most recent measurement before enrollment and must be no more than 14 days before enrollment. No transfusions are allowed within 72 hours before qualifying laboratory value.
  • Hemoglobin < 8 g/dL. Qualifying laboratory value must occur at most recent measurement before enrollment and must be no more than 14 days before enrollment. No transfusions are allowed within 72 hours before qualifying laboratory value.
  • Total bilirubin > 2X ULN ,or direct bilirubin > 2.0 mg/dL.(except patients with Gilbert's syndrome then total bilirubin >2X ULN allowed in the absence of other hepatic signs or symptoms)
  • AST or ALT > 3X ULN.
  • CrCl < 60 ml/min by Cockcroft-Gault Formula Prior Therapy or Surgery
  • Major surgery within 3 weeks prior to treatment.
  • Kyphoplasty or vertebroplasty within 1 week of enrollment.
  • Prior allogeneic stem cell transplant
  • Treatment with plasmapheresis within 4 weeks before enrollment.
  • Prior therapy with elotuzumab or any IMiD (including pomalidomide), except for prior thalidomide or lenalidomide (as defined in inclusion criteria).
  • NSAIDs, IV contrast, aminoglycosides, or other potentially nephrotoxic drugs within 2 weeks of enrollment.
  • Steroids within 3 weeks of enrollment, except:

    1. ≤ 10 mg prednisone or equivalent per day
    2. Steroid with little to no systemic absorption (ie, topical or inhaled steroids) Allergies and Adverse Drug Reaction
  • Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant protein.
  • History of Grade 4 rash associated with thalidomide treatment. Sex and Reproductive Status
  • Women of childbearing potential (WOCBP) who are pregnant or lactating or unwilling to use 2 forms of effective birth control.
  • Men who are fertile and sexually active unwilling to use 2 forms of effective birth control if their partners are WOCBP. Other Exclusion Criteria
  • Prisoners or subjects who are involuntarily incarcerated.
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02655458

Layout table for location information
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Sponsors and Collaborators
Hearn Jay Cho
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Hearn Jay Cho, MD Icahn School of Medicine at Mount Sinai

Layout table for additonal information
Responsible Party: Hearn Jay Cho, Assistant Professor, Icahn School of Medicine at Mount Sinai Identifier: NCT02655458     History of Changes
Other Study ID Numbers: GCO 15-1275
First Posted: January 14, 2016    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Keywords provided by Hearn Jay Cho, Icahn School of Medicine at Mount Sinai:
Multiple Myeloma
Induction Therapy
Autologous Stem Cell Transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Plasma Cell
Multiple Myeloma
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents